Maury Raycroft
Stock Analyst at Jefferies
(1.41)
# 3,603
Out of 5,103 analysts
55
Total ratings
33.33%
Success rate
-8.3%
Average return
Main Sectors:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Buy | $108 → $134 | $105.25 | +27.32% | 2 | Dec 2, 2025 | |
| AUPH Aurinia Pharmaceuticals | Upgrades: Buy | $10 → $21 | $15.85 | +32.49% | 1 | Nov 7, 2025 | |
| OPK OPKO Health | Downgrades: Hold | $2 → $1.6 | $1.38 | +15.94% | 1 | Oct 31, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $550 → $549 | $397.55 | +38.10% | 4 | Oct 30, 2025 | |
| KZR Kezar Life Sciences | Downgrades: Hold | $18 → $7 | $6.24 | +12.18% | 2 | Oct 17, 2025 | |
| KOD Kodiak Sciences | Initiates: Buy | $15 | $23.81 | -37.00% | 1 | Sep 22, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.39 | +46.44% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $9.70 | +446.39% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $5.16 | +55.04% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.45 | +566.67% | 1 | Dec 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $2.17 | +222.58% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $3.60 | +66.67% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $9.35 | +103.21% | 1 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $15 | $4.10 | +265.85% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $42.13 | -7.43% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.49 | +1,131.78% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.65 | +1,293.94% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $3.11 | +6,170.10% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.57 | +45.31% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $49.80 | -87.95% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $70.09 | +7.01% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $1.80 | +511.11% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $22.63 | +19.31% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $2.11 | +136.97% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $8.68 | +314.75% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.87 | +1,688.76% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $56.68 | +203.46% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.79 | +1,584.59% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $9.02 | +365.63% | 3 | Nov 1, 2017 |
Celcuity
Dec 2, 2025
Maintains: Buy
Price Target: $108 → $134
Current: $105.25
Upside: +27.32%
Aurinia Pharmaceuticals
Nov 7, 2025
Upgrades: Buy
Price Target: $10 → $21
Current: $15.85
Upside: +32.49%
OPKO Health
Oct 31, 2025
Downgrades: Hold
Price Target: $2 → $1.6
Current: $1.38
Upside: +15.94%
Alnylam Pharmaceuticals
Oct 30, 2025
Maintains: Buy
Price Target: $550 → $549
Current: $397.55
Upside: +38.10%
Kezar Life Sciences
Oct 17, 2025
Downgrades: Hold
Price Target: $18 → $7
Current: $6.24
Upside: +12.18%
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $23.81
Upside: -37.00%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.39
Upside: +46.44%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $9.70
Upside: +446.39%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $5.16
Upside: +55.04%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.45
Upside: +566.67%
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.17
Upside: +222.58%
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $3.60
Upside: +66.67%
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $9.35
Upside: +103.21%
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $4.10
Upside: +265.85%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $42.13
Upside: -7.43%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.49
Upside: +1,131.78%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.65
Upside: +1,293.94%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $3.11
Upside: +6,170.10%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.57
Upside: +45.31%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $49.80
Upside: -87.95%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $70.09
Upside: +7.01%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $1.80
Upside: +511.11%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $22.63
Upside: +19.31%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $2.11
Upside: +136.97%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $8.68
Upside: +314.75%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.87
Upside: +1,688.76%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $56.68
Upside: +203.46%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.79
Upside: +1,584.59%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $9.02
Upside: +365.63%